丙型肝炎病毒消除后食欲相关分子的可能改变。
Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus.
机构信息
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.
Wakakusa-Daiichi Hospital, Higashiosaka, Japan.
出版信息
In Vivo. 2022 May-Jun;36(3):1491-1496. doi: 10.21873/invivo.12856.
BACKGROUND/AIM: Recent advances in antiviral treatment have achieved a sustained viral response (SVR) in over 95% of hepatitis C virus (HCV) infections. HCV elimination is suggested to improve several lifestyle-related factors; however, few studies have focused on dietary habit-/appetite-related factors.
PATIENTS AND METHODS
HCV-infected patients who received Daclatasvir/Asnaprevir (DCV/ASV) therapy were enrolled, and the changes in appetite-related molecules after antiviral therapy were assessed with a multiple cytokine-measuring system.
RESULTS
Among 119 HCV-infected patients who received DCV/ASV treatment, 104 (87.3%) achieved an SVR. In the SVR group, DCV/ASV treatment improved several liver-related variables at 24 weeks after the completion of therapy. In patients with an SVR, the values of glucagon-like peptide 1 (GLP-1) and leptin were significantly increased at 24 weeks after completing direct-acting antiviral therapy. However, no significant change was observed in non-SVR patients, regardless of the receipt of direct-acting antiviral treatment.
CONCLUSION
Gastrointestinal hormones related to the dietary habit and/or appetite may be influenced by HCV elimination.
背景/目的：抗病毒治疗的最新进展使超过 95%的丙型肝炎病毒（HCV）感染者实现了持续病毒学应答（SVR）。HCV 的清除被认为可以改善多种与生活方式相关的因素；然而，很少有研究关注与饮食习惯/食欲相关的因素。
患者和方法
本研究纳入了接受达卡他韦/阿舒瑞韦（DCV/ASV）治疗的 HCV 感染患者，并使用多种细胞因子检测系统评估抗病毒治疗后与食欲相关的分子的变化。
结果
在接受 DCV/ASV 治疗的 119 例 HCV 感染患者中，有 104 例（87.3%）达到了 SVR。在 SVR 组中，DCV/ASV 治疗在治疗完成后 24 周改善了几项与肝脏相关的变量。在达到 SVR 的患者中，在完成直接作用抗病毒治疗后 24 周时，胰高血糖素样肽 1（GLP-1）和瘦素的值显著增加。然而，在未达到 SVR 的患者中，无论是否接受直接作用抗病毒治疗，均未观察到明显变化。
结论
与饮食习惯和/或食欲相关的胃肠激素可能受 HCV 清除的影响。
Zotero 插件